Pharmacokinetics of diclofenac potassium after oral administration of sachets and tablets
https://doi.org/10.14412/1996-7012-2008-491
Abstract
Results. There is evidence that patients tolerate both its sachets and tablets equally well, as confirmed by subjective and objective observations. There are neither marked side effects nor considerable changes in laboratory tests and in the values of vital functions. Diclofenac potassium as early-action tablets (50 and 100 mg) exerts a very good analgesic effect in treating migraine since the plasma concentration of the drug peaks on an average of an hour of administration (range 0,33-2 hours) and the analgesic effect developed following 60-90 min. Conclusion. By comparing the rate of absorption, it may be concluded that diclofenac potassium as sachets will produce a much rapider analgesic effect. Thus, the high solubility of diclofenac potassium and its very good absorbability (as sachets in particular) make the drug a superior analgesic that has a rapid analgesic activity.
About the Authors
A MartsoL D Bo
F Verga
N Ts Monti
G Abbondati
R A Tettamanti
F Krivelli
M R Ur
Sh Ismaili
A Marzo
L D Bo
F Verga
H Z Monti
G Abbondati
R A Tettamanti
F Crivelli
M R Ur
Sh Ismaili
References
1. <div><p>Martindale - The Extra Pharmacopoeia 31 st Ed., p. 36-37. The Royal Pharmaceutical Society, London, 1996.</p><p>Todd P.A., Sorkin E.M. Diclofenac sodium: a reappraisal of its pharmacodynamic and pharmaco-kinetic properties and therapeutic efficacy. Drugs 35, 244 regulations for continuing clinical trials. Pharmacol Res 1998; 37: 321.</p><p>Shah V.P., Midha K.K., Dighe S. et al. Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. J Pharm Sci 1992; 81: 309.</p><p>Marzo A. Pharmacokinetic analysis, bioavailability and operating guidelines. J Pharm Pharmacol 1997; 49: 1259.</p><p>Marzo A., Ceppi Monti N. Acceptable and unacceptable procedures in bioavailability and bioequiva- lence trials. Pharmacol Res 1998; 38: 401.</p><p>Anonymous. CPMP. Note for guidance on the investigation of bioavailability and bioequiva-lence. CPMP / EWP / QWP / 1401 /98 draft. December 1998. 7</p><p>Anonymous. In vivo Bioequivalence Guidances/General Information. United States Pharmacopoeia 1998; 23: (suppl. 8): 4382.</p><p>Schuimann D. 1, A comparison of the two onesided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987; 15: 657.</p><p>Riess W., Stierlin H., Degen P. et al. Pharmacokinetics and metabolism of the anli-inflammatory agent voltaren. Scand J Rheumatol 1978; (suppl. 22): 17.</p><p>Derendorf H., Mullersman G., Bart J. et al. Pharmacokinetics diclofenac sodium after intramuscular administration in combination with triamci-nolone acetate. Eur J Clin Pharmacol 1986; 31: 263.</p><p>Davies H.M., Anderson K.E. Clinical phutnia-cokinetic of diclofenac. Therapeutic insights and pitfalls Clin Pharmacokinet 1997; 33: 184.</p><p>McNeely W., Goa K.L. Diclofenac-potassium in migraine. A review Drugs 1999; 57: 991.</p></div><br />
Review
For citations:
Martso A, Bo LD, Verga F, Monti NT, Abbondati G, Tettamanti RA, Krivelli F, Ur MR, Ismaili S, Marzo A, Bo LD, Verga F, Monti HZ, Abbondati G, Tettamanti RA, Crivelli F, Ur MR, Ismaili S. Pharmacokinetics of diclofenac potassium after oral administration of sachets and tablets. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2008;2(3):59-63. (In Russ.) https://doi.org/10.14412/1996-7012-2008-491